Cell News and Research

RSS

Combination therapy improves overall survival in women with advanced breast cancer

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

14 Dec 2009

Texas researchers identify new detection method for circulating tumor cells

Circulating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Incyte Corporation announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.

14 Dec 2009

Study examines the association of BRCA1 gene, infertility and breast/ovarian cancer

In a study published online this week in the leading cancer journal, Journal of Clinical Oncology, Westchester Medical Center Physician Dr. Kutluk Oktay, MD, Director, Division of Reproductive Medicine & Infertility concluded that mutations in the BRCA1 gene (gene associated with early onset breast cancer) are associated with early diminishment of egg reserve.

14 Dec 2009

Researchers explore regenerative techniques to treat common neurological disorders

For more than 400 years, scientists have studied the amazing regenerative power of salamanders, trying to understand how these creatures routinely repair injuries that would usually leave humans and other mammals paralyzed -- or worse.

14 Dec 2009

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of positive trastuzumab-DM1 (T-DM1) clinical data at the 32nd Annual San Antonio Breast Cancer Symposium (Abstract #710).

14 Dec 2009

Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics

Celldex Therapeutics, Inc. today announced the results of a positive Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers.

13 Dec 2009

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

A modified blood adult stem-cell transplant regimen has effectively reversed sickle cell disease in 9 of 10 adults who had been severely affected by the disease, according to results of a National Institutes of Health study in the Dec. 10 issue of the New England Journal of Medicine.

13 Dec 2009

Clinical trial of 2009 H1N1 influenza vaccine

HIV-infected adults currently are being recruited to participate in a clinical trial of 2009 H1N1 influenza vaccine. The study, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health, will enroll approximately 240 men and women between the ages of 18 and 64.

13 Dec 2009

SOCS1 molecule prevents cancer-causing activity of cytokines, discover researchers

Canadian researchers have discovered a novel molecular mechanism that prevents cancer. In the December 11 edition of the prestigious journal Molecular Cell, scientists from the Universit- de Montr-al and the Universit- de Sherbrooke explain how they found that the SOCS1 molecule prevents the cancer-causing activity of cytokines, hormones that are culprits in cancer-prone chronic inflammation diseases such as Crohns, in smokers and people exposed to asbestos.

12 Dec 2009

Lapatinib plus trastuzumab extend lives of HER2-positive breast cancer patients

Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center.

12 Dec 2009

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML).

11 Dec 2009

HTDS comments on its recent stock price activity

Hard to Treat Diseases (HTDS) http://www.htdsmedical.com the company has been asked to comment on recent activity in its stock price. First, we would like our shareholders to be reassured and take comfort in the fact that there is no news that they do not know about. While there are several significant pending transactions they are not ready to be announced yet, however will be in due and appropriate time.

11 Dec 2009

Zevalin clinical data presented at 2009 ASH meeting

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN (ibritumomab tiuxetan) was presented at the 51st Annual Meeting of the American Society of Hematology (ASH), which was held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

11 Dec 2009

CyMap technology wins first prize in the Medical and Healthcare category

CyMap, an innovative lens-free microscope developed by Cancer Research UK scientists and members of the Optical Biochips Consortium*, has won first prize in the Medical and Healthcare category of The Engineer's Technology and Innovation Awards as well as the overall Grand Prix prize.

11 Dec 2009

Financial results for second fiscal quarter announced by China Cord Blood

China Cord Blood Corporation ("CCBC" or "the Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced its unaudited financial results for the quarter and six months ended September 30, 2009.

11 Dec 2009

Circassia raises GBP15M for development of its novel allergy T-cell vaccines portfolio

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has completed a GBP15 million ($25 million) fundraising. The investment round, which was led by Imperial Innovations and supported by existing shareholders including Invesco Perpetual and Lansdowne Partners, was significantly oversubscribed and is the company's third successful fundraising.

11 Dec 2009

Cell News and Research

Combination therapy improves overall survival in women with advanced breast cancer

Texas researchers identify new detection method for circulating tumor cells

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Study examines the association of BRCA1 gene, infertility and breast/ovarian cancer

Researchers explore regenerative techniques to treat common neurological disorders

ImmunoGen announces the presentation of positive trastuzumab-DM1 clinical data

Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics

Modified blood adult stem-cell transplant regimen reverses sickle cell disease

Clinical trial of 2009 H1N1 influenza vaccine

SOCS1 molecule prevents cancer-causing activity of cytokines, discover researchers

Lapatinib plus trastuzumab extend lives of HER2-positive breast cancer patients

Phase 2 pivotal trial of AC220 initiated by Ambit Biosciences

HTDS comments on its recent stock price activity

Zevalin clinical data presented at 2009 ASH meeting

CyMap technology wins first prize in the Medical and Healthcare category

Financial results for second fiscal quarter announced by China Cord Blood

Circassia raises GBP15M for development of its novel allergy T-cell vaccines portfolio

Brandeis researchers reveal the hidden, transient life of protein between active states

Study may help in treating sex differentiation disorders in children

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News